ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410

Its studies are mostly in Uterine Cervical Neoplasms · Lymphoma, led by L & L Bio Co., Ltd., Ningbo, China.

Drug pageAnti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 4, 20253 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
L & L Bio Co., Ltd., Ningbo, China33 open or runningphase 3since Sep 4, 2025Apr 27, 2022Dec 30, 2026phase 2 · NCT06468358

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2022First study: phase 1 study in LymphomaFirst studyNCT05357651 · 100 planned · China
  2. May 31, 2024Phase 2 study in Solid TumorNCT06468358 · 194 planned · China
  3. Sep 4, 2025Phase 3 study in Uterine Cervical NeoplasmsNCT07177716 · 120 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 2 study in Solid TumorNCT06468358
  2. Dec 30, 2026Primary completion: phase 1 study in LymphomaNCT05357651
  3. Dec 2028Primary completion: phase 3 study in Uterine Cervical NeoplasmsNCT07177716

TargetBeta

“A recombinant humanized bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cell”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07177716Uterine Cervical Neoplasms · China3Not yet recruitingDec 2028120
NCT06468358Solid Tumor · China2RecruitingDec 30, 2026194
NCT05357651Lymphoma · China1RecruitingDec 30, 2026100

How it is read

Names in the registry

  • “LB1410”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.